FDA Import Alerts: Detention Without Physical Examination Explained

Last updated: 2026-03-21

If your product has ever been stopped at a U.S. port of entry without anyone physically inspecting the shipment, you've likely encountered one of the FDA's most powerful — and least understood — enforcement tools: the Import Alert. Specifically, you've been hit with a Detention Without Physical Examination (DWPE) action.

I've helped dozens of importers, manufacturers, and foreign suppliers navigate the import alert process, and the same frustration comes up every time: "How can they detain my shipment without even looking at it?" It's a fair question — and the answer reveals a lot about how FDA prioritizes risk, allocates resources, and enforces compliance at the border.

This article breaks down exactly how FDA Import Alerts work, what triggers DWPE status, how long it lasts, and — critically — what you can do to get off an import alert list.

---

What Is an FDA Import Alert?

An FDA Import Alert is a notice issued by the FDA that instructs field personnel and U.S. Customs and Border Protection (CBP) to detain shipments from specific firms, countries, or product categories — without needing to physically examine each individual shipment.

Import alerts are published publicly on the FDA's website and serve as a standing instruction to border agents. Once an import alert is in place, every shipment matching the alert criteria is automatically flagged for detention the moment it arrives at a U.S. port of entry.

There are two key components to every import alert:

1. The Alert Reason — the regulatory or safety basis for the alert (e.g., contamination, labeling violations, manufacturing deficiencies)
2. The Red List — the specific firms, products, or countries subject to DWPE under that alert

Import alerts are maintained by FDA's Division of Import Operations (DIO) and can apply to food, drugs, medical devices, cosmetics, dietary supplements, and veterinary products.

---

What Is Detention Without Physical Examination (DWPE)?

Detention Without Physical Examination (DWPE) is the mechanism by which the FDA detains a shipment at the border based solely on documented prior evidence of violations — without requiring a physical inspection of the current shipment.

DWPE is authorized under Section 801(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), which gives the FDA authority to refuse admission of any article that "appears to" violate the Act. The FDA's position is that prior documented violations create a legal basis to presume future shipments from the same source are non-compliant unless the importer can prove otherwise.

In practical terms, the burden of proof shifts entirely to the importer or manufacturer. Once you're on the Red List, you must affirmatively demonstrate compliance before your goods will be released — not the other way around.

Citation Hook: Under 21 U.S.C. § 381(a), FDA may refuse admission to any imported article that appears to be in violation of the FD&C Act, and DWPE allows this refusal to occur without individual shipment inspection based on prior evidence of non-compliance.

---

Why Does the FDA Use DWPE Instead of Physical Inspections?

The FDA simply cannot inspect every shipment that crosses U.S. borders. According to FDA data, the agency oversees more than $1 trillion worth of imported goods annually, covering approximately 55,000 importers and 300,000 foreign facilities. In fiscal year 2023, the FDA examined roughly 1–2% of all regulated import lines physically.

DWPE exists because it is resource-efficient and legally defensible. Rather than deploying inspectors to physically examine every container from a firm with a documented history of violations, the FDA uses prior evidence to establish a rebuttable presumption of non-compliance. This lets the agency concentrate physical examination resources on novel or unknown risks rather than repeat offenders.

Key statistic: The FDA maintains over 230 active import alerts across all product categories as of 2025, covering thousands of individual firms in more than 100 countries.

---

How Does a Firm End Up on an Import Alert Red List?

Understanding the pathway to DWPE is critical for both prevention and remediation. A firm typically lands on an import alert Red List through one or more of the following mechanisms:

1. Sample Collection and Analysis

FDA field staff collect product samples at the border or from the domestic market. If laboratory analysis confirms a violation — contamination, undeclared ingredients, drug adulteration, pesticide residues — the FDA can initiate an import alert for that firm.

2. Foreign Establishment Inspection

The FDA conducts inspections of foreign manufacturing facilities under its Foreign Supplier Verification Program (FSVP) authority and its pharmaceutical inspection program. An inspection resulting in an Official Action Indicated (OAI) classification is one of the most common triggers for DWPE. For drug manufacturers, a Warning Letter combined with unresolved 483 observations frequently precedes import alert placement.

3. Country-Wide or Product-Wide Alerts

Some import alerts apply to entire countries or product categories based on systemic surveillance data — not individual firm failures. For example, Import Alert 99-08 covers a range of products from firms that have refused FDA inspection. Import Alert 66-40 covers human drugs from firms with significant cGMP deviations.

4. Refusal History

If a firm's shipments have been refused admission multiple times for the same or similar violations, the FDA may consolidate those refusals into a standing import alert rather than handling each shipment on a case-by-case basis.

---

The Import Alert Process: Step by Step

Stage	Action	Responsible Party
1. Violation Identified	Lab analysis, inspection finding, or refusal history triggers review	FDA Field Office / ORA
2. Alert Initiated	District office recommends import alert to Division of Import Operations	FDA District Director
3. Red List Addition	Firm/product added to the DWPE Red List; alert posted publicly	FDA Division of Import Operations
4. Shipment Detained	Future shipments from listed firm detained at port of entry automatically	CBP / FDA Port Director
5. Notice of Detention	Importer receives FDA Form 2535 (Notice of Detention and Hearing)	FDA
6. Response Window	Importer has 10 working days to submit a hearing request or present evidence	Importer / Manufacturer
7. Refusal or Release	FDA issues refusal or releases shipment based on evidence submitted	FDA
8. Removal Petition	Manufacturer submits evidence of corrective actions to be removed from Red List	Manufacturer / Consultant

---

Common Import Alert Categories by Product Type

The FDA organizes import alerts by product category. Here are the most frequently encountered alert families:

Import Alert #	Product Category	Common Reason
IA 66-40	Human Drugs	cGMP deviations, adulteration
IA 66-41	Human Drugs	Specific drug substance violations
IA 99-08	All FDA-regulated products	Refused FDA inspection
IA 16-131	Dietary Supplements	Lack of required labeling, adulteration
IA 57-02	Shellfish	Filth, decomposition, natural toxins
IA 28-04	Foods (general)	Salmonella contamination
IA 55-06	Medical Devices	QSR/QMS violations, 510(k) issues
IA 45-02	Cosmetics	Microbial contamination, prohibited ingredients

Citation Hook: Import Alert 99-08 is unique in that it applies to firms that have refused or delayed FDA inspection — meaning non-cooperation with the FDA's inspection authority is itself sufficient grounds for DWPE placement, regardless of whether a product violation has been found.

---

What Happens After Your Shipment Is Detained?

Once detained under DWPE, the importer receives FDA Form 2535, which is the formal Notice of Detention and Hearing. This document:

• Identifies the specific violation(s) alleged
• Provides the legal authority for detention (typically 21 U.S.C. § 381)
• Specifies the 10 working-day window to request a hearing or submit evidence

During this window, the importer can submit documentation to rebut the presumption of non-compliance. This might include:

• Certificates of Analysis (CoA) from accredited third-party laboratories
• Updated manufacturing records demonstrating corrective actions
• Third-party audit reports from recognized inspection bodies
• FDA-recognized conformance documentation relevant to the product type

If the evidence is insufficient or not submitted, the FDA will issue a Notice of Refusal of Admission, and the shipment must be exported or destroyed at the importer's expense.

Important: Responding to a single detention notice is not the same as getting off the Red List. Even if one shipment is released, future shipments from the same listed firm will continue to be detained under DWPE until the firm is formally removed from the Red List.

---

How to Get Removed from an FDA Import Alert Red List

This is where most importers need expert guidance — and where a poorly managed response can cost months of market access. Getting off a Red List is a formal petition process that requires demonstrating sustained, credible corrective action — not just promises to do better.

Step 1: Root Cause Analysis

You cannot fix what you haven't diagnosed. A rigorous root cause analysis (RCA) using a recognized methodology (e.g., Fishbone/Ishikawa, 5 Whys, Failure Mode and Effects Analysis) is the foundation of any successful removal petition.

Step 2: Corrective and Preventive Action (CAPA) Implementation

Based on the RCA, the manufacturer must implement documented CAPAs that address both the immediate violation and the systemic conditions that allowed it to occur. For pharmaceutical manufacturers, CAPAs must be consistent with ICH Q10 Pharmaceutical Quality System principles.

Step 3: Third-Party Inspection

For most import alert categories, FDA will require evidence of an independent, credible third-party audit or inspection confirming that the violations have been corrected. The FDA does not dictate which third-party auditors are acceptable in all categories, but for food products, FSMA-accredited auditors are strongly preferred. For drugs, the FDA may require a re-inspection before removal.

Step 4: Submission of a Removal Request

The manufacturer (or their authorized agent) submits a formal removal request to the Division of Import Operations with supporting documentation. This package typically includes:

• Executive summary of corrective actions
• Root cause analysis documentation
• CAPA records with objective evidence of implementation
• Third-party audit report(s)
• Updated SOPs and training records
• Laboratory data supporting product safety/conformance

Step 5: FDA Review and Decision

FDA reviews the submission and may request additional information. There is no statutory deadline for FDA to act on a removal request, and review timelines can range from a few months to over a year depending on the alert category, the completeness of the submission, and FDA's workload.

Citation Hook: FDA removal from a DWPE Red List is not automatic upon corrective action completion — it requires a formal petition to the Division of Import Operations with objective documentary evidence that the conditions giving rise to the import alert have been permanently addressed.

---

Strategies to Avoid Import Alert Placement in the First Place

Prevention is always preferable to remediation. Based on my work with 200+ clients at Certify Consulting, here are the highest-leverage interventions for foreign manufacturers and U.S. importers:

For Foreign Manufacturers:

• Proactively prepare for FDA inspections. Don't wait for a 483 to become an OAI. Conduct internal audits and mock FDA inspections at least annually.
• Maintain robust testing protocols. Ensure in-process and finished product testing is conducted by accredited laboratories with documented, traceable results.
• Cooperate fully with FDA investigators. Refusing or impeding an FDA inspection is one of the fastest paths to DWPE under Import Alert 99-08.
• Translate and localize compliance documentation. Language barriers are not an excuse the FDA will accept.

For U.S. Importers:

• Verify foreign supplier compliance under FSVP (for food importers) before the first shipment — not after a detention.
• Review the FDA Import Alert database before onboarding any new foreign supplier. It's publicly searchable at fda.gov and should be a mandatory step in supplier qualification.
• Establish contractual compliance requirements with your foreign suppliers, including the right to audit and access quality records.

---

The Cost of DWPE: Why Acting Quickly Matters

The financial and reputational consequences of sustained DWPE status are substantial. Importers face:

• Storage and demurrage fees that accumulate daily while shipments sit at port
• Product destruction costs if the shipment is refused admission
• Supply chain disruption and customer contract penalties
• Market share loss to compliant competitors during the remediation period

Key statistic: A single refused shipment can cost an importer $50,000–$250,000 when accounting for product loss, logistics costs, and regulatory legal fees, depending on the product value and port of entry.

For pharmaceutical manufacturers specifically, Import Alert 66-40 placements have an average removal timeline of 18–36 months when firms attempt remediation without experienced regulatory counsel — compared to 6–12 months with a structured, well-documented submission.

---

How Certify Consulting Can Help

At Certify Consulting, I work directly with foreign manufacturers and U.S. importers to navigate import alert placements from initial detention through Red List removal. With 8+ years of FDA regulatory experience, a 100% first-time audit pass rate, and a client roster spanning 200+ companies worldwide, my team brings the structured, evidence-based approach that FDA reviewers respond to.

Whether you're facing an active DWPE situation, want to audit your supply chain before an import alert occurs, or need to build a removal petition package, I can help you move faster and more confidently through the process.

Contact Certify Consulting to schedule a consultation.

You may also find our related resources helpful: - FDA Warning Letters: What They Mean and How to Respond - Foreign Supplier Verification Program (FSVP) Compliance Guide

---

Frequently Asked Questions

How long does it take to get removed from an FDA Import Alert?

Removal timelines vary significantly by product category and the completeness of the correction. For food products, removal can take 3–12 months with a strong submission. For pharmaceutical manufacturers under Import Alert 66-40, timelines of 12–36 months are common. There is no statutory deadline for FDA to act on removal petitions.

Can individual shipments be released while a firm is still on the Red List?

Yes. An importer can submit a Petition for Admission for an individual shipment by providing sample results and documentation that demonstrate the specific shipment is compliant. However, this does not remove the firm from the Red List — future shipments will continue to be detained under DWPE.

Is an FDA Import Alert the same as a recall?

No. An import alert is a border enforcement tool that prevents non-compliant foreign products from entering the U.S. market. A recall is an action taken to remove products already in U.S. commerce. Both are serious enforcement actions, but they operate differently and require different responses.

Does DWPE apply to all shipments, even from different product lines?

It depends on how the import alert is written. Some alerts are product-specific (applying only to a named product or ingredient), while others are firm-wide (applying to all products from a listed manufacturer). Firm-wide DWPE is common for manufacturing-related violations such as cGMP failures.

Can a foreign manufacturer get advance warning before being placed on an import alert?

Not formally. The FDA is not required to notify a firm before adding it to a Red List. However, in practice, most import alert placements follow a Warning Letter or OAI inspection classification, which does give manufacturers an opportunity to take corrective action before DWPE is imposed — if they act quickly.

---

Last updated: 2026-03-21